156 related articles for article (PubMed ID: 12915681)
1. Effect of combined AT1 receptor and aldosterone receptor antagonism on plasminogen activator inhibitor-1.
Sawathiparnich P; Murphey LJ; Kumar S; Vaughan DE; Brown NJ
J Clin Endocrinol Metab; 2003 Aug; 88(8):3867-73. PubMed ID: 12915681
[TBL] [Abstract][Full Text] [Related]
2. Differing effects of mineralocorticoid receptor-dependent and -independent potassium-sparing diuretics on fibrinolytic balance.
Ma J; Albornoz F; Yu C; Byrne DW; Vaughan DE; Brown NJ
Hypertension; 2005 Aug; 46(2):313-20. PubMed ID: 15998706
[TBL] [Abstract][Full Text] [Related]
3. Spironolactone abolishes the relationship between aldosterone and plasminogen activator inhibitor-1 in humans.
Sawathiparnich P; Kumar S; Vaughan DE; Brown NJ
J Clin Endocrinol Metab; 2002 Feb; 87(2):448-52. PubMed ID: 11836266
[TBL] [Abstract][Full Text] [Related]
4. Role of angiotensin II in plasma PAI-1 changes induced by imidapril or candesartan in hypertensive patients with metabolic syndrome.
Fogari R; Zoppi A; Mugellini A; Maffioli P; Lazzari P; Derosa G
Hypertens Res; 2011 Dec; 34(12):1321-6. PubMed ID: 21814211
[TBL] [Abstract][Full Text] [Related]
5. Aldosterone modulates plasminogen activator inhibitor-1 and glomerulosclerosis in vivo.
Brown NJ; Nakamura S; Ma L; Nakamura I; Donnert E; Freeman M; Vaughan DE; Fogo AB
Kidney Int; 2000 Sep; 58(3):1219-27. PubMed ID: 10972684
[TBL] [Abstract][Full Text] [Related]
6. Effects of aldosterone and angiotensin II receptor blockade on cardiac angiotensinogen and angiotensin-converting enzyme 2 expression in Dahl salt-sensitive hypertensive rats.
Takeda Y; Zhu A; Yoneda T; Usukura M; Takata H; Yamagishi M
Am J Hypertens; 2007 Oct; 20(10):1119-24. PubMed ID: 17903697
[TBL] [Abstract][Full Text] [Related]
7. Fibrinolysis and insulin sensitivity in imidapril and candesartan (FISIC study) recipients with hypertension.
Fogari R; Zoppi A; Salvadeo SA; Mugellini A; Lazzari P; Santoro T; Derosa G
Hypertens Res; 2011 Apr; 34(4):509-15. PubMed ID: 21179101
[TBL] [Abstract][Full Text] [Related]
8. Aldosterone and not plasminogen activator inhibitor-1 is a critical mediator of early angiotensin II/NG-nitro-L-arginine methyl ester-induced myocardial injury.
Oestreicher EM; Martinez-Vasquez D; Stone JR; Jonasson L; Roubsanthisuk W; Mukasa K; Adler GK
Circulation; 2003 Nov; 108(20):2517-23. PubMed ID: 14581407
[TBL] [Abstract][Full Text] [Related]
9. Comparative effect of angiotensin-converting enzyme inhibition and angiotensin II type 1 receptor antagonism on plasma fibrinolytic balance in humans.
Brown NJ; Agirbasli M; Vaughan DE
Hypertension; 1999 Aug; 34(2):285-90. PubMed ID: 10454455
[TBL] [Abstract][Full Text] [Related]
10. Activation of the aldosterone/mineralocorticoid receptor system and protective effects of mineralocorticoid receptor antagonism in retinal ischemia-reperfusion injury.
Liu Y; Hirooka K; Nishiyama A; Lei B; Nakamura T; Itano T; Fujita T; Zhang J; Shiraga F
Exp Eye Res; 2012 Mar; 96(1):116-23. PubMed ID: 22200488
[TBL] [Abstract][Full Text] [Related]
11. Angiotensin II induces interleukin-6 in humans through a mineralocorticoid receptor-dependent mechanism.
Luther JM; Gainer JV; Murphey LJ; Yu C; Vaughan DE; Morrow JD; Brown NJ
Hypertension; 2006 Dec; 48(6):1050-7. PubMed ID: 17043157
[TBL] [Abstract][Full Text] [Related]
12. Central mineralocorticoid receptors and the role of angiotensin II and glutamate in the paraventricular nucleus of rats with angiotensin II-induced hypertension.
Gabor A; Leenen FH
Hypertension; 2013 May; 61(5):1083-90. PubMed ID: 23509081
[TBL] [Abstract][Full Text] [Related]
13. Renin-angiotensin system and myocardial collagen matrix: modulation of cardiac fibroblast function by angiotensin II type 1 receptor antagonism.
Brilla CG; Scheer C; Rupp H
J Hypertens Suppl; 1997 Dec; 15(6):S13-9. PubMed ID: 9493122
[TBL] [Abstract][Full Text] [Related]
14. Effect of spironolactone on impaired fibrinolysis of hypertensive patients.
Yalcin AI; Dincer M; Aslan V; Gulbas Z
Kidney Blood Press Res; 2002; 25(4):260-4. PubMed ID: 12424430
[TBL] [Abstract][Full Text] [Related]
15. Vasoconstrictor effect of aldosterone via angiotensin II type 1 (AT1) receptor: possible role of AT1 receptor dimerization.
Yamada M; Kushibiki M; Osanai T; Tomita H; Okumura K
Cardiovasc Res; 2008 Jul; 79(1):169-78. PubMed ID: 18326554
[TBL] [Abstract][Full Text] [Related]
16. Synergistic effect of adrenal steroids and angiotensin II on plasminogen activator inhibitor-1 production.
Brown NJ; Kim KS; Chen YQ; Blevins LS; Nadeau JH; Meranze SG; Vaughan DE
J Clin Endocrinol Metab; 2000 Jan; 85(1):336-44. PubMed ID: 10634408
[TBL] [Abstract][Full Text] [Related]
17. Effect of the angiotensin II receptor blocker candesartan on fibrinolysis in patients with mild hypertension.
Skurk T; Lee YM; Nicuta-Rölfs TO; Haastert B; Wirth A; Hauner H
Diabetes Obes Metab; 2004 Jan; 6(1):56-62. PubMed ID: 14686964
[TBL] [Abstract][Full Text] [Related]
18. A dynamic comparative study concerning the effects of angiotensin-converting enzyme inhibitors and aldosterone receptor blockers on the fibrinolytic system.
Usalan C; Buyukhatipoglu H
Clin Appl Thromb Hemost; 2008 Apr; 14(2):203-9. PubMed ID: 18372278
[TBL] [Abstract][Full Text] [Related]
19. Plasminogen activator inhibitor-1 expression is regulated by the angiotensin type 1 receptor in vivo.
Nakamura S; Nakamura I; Ma L; Vaughan DE; Fogo AB
Kidney Int; 2000 Jul; 58(1):251-9. PubMed ID: 10886570
[TBL] [Abstract][Full Text] [Related]
20. Effect of amiloride and spironolactone on renal tubular function and central blood pressure in patients with arterial hypertension during baseline conditions and after furosemide: a double-blinded, randomized, placebo-controlled crossover trial.
Matthesen SK; Larsen T; Vase H; Lauridsen TG; Jensen JM; Pedersen EB
Clin Exp Hypertens; 2013; 35(5):313-24. PubMed ID: 22966789
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
